• Disease
  • Mantle
  • Mantle Cell
  • Mantle Cell Lymphoma
  • Martin H Dreyling

    Prominent publications by Martin H Dreyling

    KOL Index score: 17868

    BACKGROUND: Follicular lymphoma is characterized by slow growth and an initially high rate of response to treatment, but patients typically relapse and experience progressive disease. Rituximab in combination with chemotherapy has been shown to improve overall survival in patients with follicular lymphoma compared with chemotherapy alone, but data from randomized clinical trials evaluating rituximab maintenance treatment in these patients are limited. We aimed to evaluate the effect of ...

    Also Ranks for: Rituximab Maintenance |  follicular lymphoma |  monoclonal antibodies |  95 patients |  systematic review metaanalysis
    KOL Index score: 16934

    BACKGROUND: Indolent B cell lymphoid malignancies include follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma and marginal zone lymphomas. Chronic lymphocytic leukaemia (CLL) is a lymphoid malignancy similar to small lymphocytic lymphoma (SLL) in its leukaemic phase.Indolent lymphoid malignancies including CLL are characterised by slow growth, a high initial response rate and a relapsing and progressive disease course. Advanced-stage indolent ...

    Also Ranks for: Bendamustine Patients |  chronic lymphocytic leukaemia |  cell lymphoma |  malignancies including |  compared chemotherapy
    KOL Index score: 16769

    Gene silencing of DNA repair genes hMLH1 and MGMT caused by aberrant promoter methylation has been detected in various solid tumors. However, in acute myeloid leukemia (AML) the frequency of hMLH1 and MGMT promoter methylation is not yet fully elucidated. To determine the methylation status and expression of hMLH1 and MGMT, we investigated 22 AML cases by methylation-specific polymerase chain reaction (MS-PCR) and reverse transcription PCR (RT-PCR). To exclude unspecific PCR ...

    Also Ranks for: Promoter Methylation |  acute myeloid leukemia |  dna repair |  hmlh1 mgmt |  myeloid aml
    KOL Index score: 16409

    BACKGROUND: Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) given a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) relapse or develop refractory disease. Lenalidomide has high activity in relapsed or refractory aggressive B-cell lymphomas. In phase 2 of the REAL07 trial, we aimed to establish the safety and efficacy of the combination of lenalidomide and R-CHOP21 in elderly patients with ...

    Also Ranks for: Elderly Patients |  2 trial |  untreated diffuse |  large bcell |  cell lymphoma
    KOL Index score: 16366

    PURPOSE: Mantle cell lymphoma (MCL) is characterized by a poor prognosis with a low to moderate sensitivity to chemotherapy and a median survival of only 3 to 4 years. In an attempt to improve outcome, the German Low Grade Lymphoma Study Group (GLSG) initiated a randomized trial comparing the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and rituximab (R-CHOP) with CHOP alone as first-line therapy for advanced-stage MCL.


    Also Ranks for: Treatment Failure |  cell lymphoma |  rchop patients |  doxorubicin vincristine |  prednisone chop
    KOL Index score: 16093

    In follicular lymphoma (FL) and mantle cell lymphoma (MCL) the monoclonal antibody rituximab (R) improves the prognosis when combined with chemotherapy. The present study investigated R-maintenance after R-chemotherapy. Patients with recurring or refractory FL and MCL were randomized to 4 courses of fludarabine, cyclophosphamide, and mitoxantrone (FCM) alone or combined with R (R-FCM). Responding patients underwent a second randomization for R-maintenance comprising 2 further courses of ...

    Also Ranks for: Response Duration |  salvage therapy |  antibodies monoclonal antibodies |  refractory follicular |  cyclophosphamide mitoxantrone
    KOL Index score: 15476

    BACKGROUND: Addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy (R-chemo) has been shown to improve response rates and progression-free survival in patients with indolent or mantle cell lymphoma. However, the impact of R-chemo on overall survival is unclear. We performed a comprehensive systematic review and meta-analysis to examine the efficacy of combined immunochemotherapy using R-chemo compared with the identical chemotherapy alone with respect to overall survival ...

    Also Ranks for: Mantle Cell Lymphoma |  chemotherapy patients |  rchemo survival |  monoclonal antibodies monoclonal |  mortality 95
    KOL Index score: 15447

    BACKGROUND: Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 study was to compare rituximab plus pola (R-pola) or pina (R-pina) in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

    METHODS: In this phase 2 randomised study at 39 investigational sites in six countries, patients were randomly ...

    Also Ranks for: Pinatuzumab Vedotin |  follicular lymphoma |  complete response |  phase 2 |  pola patients
    KOL Index score: 15031

    BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.

    METHODS: This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell ...

    Also Ranks for: Cell Lymphoma |  refractory mantle |  temsirolimus patients |  ibrutinib versus |  progressionfree survival
    KOL Index score: 14518

    In follicular lymphoma (FL) and mantle cell lymphoma (MCL) the monoclonal antibody rituximab may improve the prognosis when combined with chemotherapy. This was investigated in a prospective randomized study in patients with relapsed disease. A total of 147 patients were randomized to receive 4 courses of chemotherapy with 25 mg/m(2) fludarabine on days 1 to 3, 200 mg/m(2) cyclophosphamide on days 1 to 3, and 8 mg/m(2) mitoxantrone on day 1 (FCM), alone or combined with rituximab (375 ...

    Also Ranks for: Lymphoma Study |  prospective randomized |  antibodies monoclonal antibodies |  rituximab survival |  mantle cell
    KOL Index score: 13966

    BACKGROUND: The increasing application of multi-color flow cytometry assays for staging and follow-up in mantle cell lymphoma necessitates that the specificity and sensitivity of this technique are evaluated. Data from prospective clinical trials comparing the clinical applicability of flow cytometry to routine diagnostic methods and to polymerase chain reaction are currently lacking.

    DESIGN AND METHODS: We applied a standardized four-color flow cytometry assay to 281 prospectively ...

    Also Ranks for: Flow Cytometry |  mantle cell lymphoma |  chain reaction |  residual disease |  consensus igh
    KOL Index score: 13750

    Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current study, 428 patients with untreated, advanced-stage FL were randomly assigned for therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone (n = 205) or CHOP combined with rituximab (R-CHOP) (n = 223). R-CHOP reduced the relative risk for treatment failure by 60% and significantly ...

    Also Ranks for: Follicular Lymphoma |  frontline therapy |  rchop chop |  antibodies monoclonal antibodies |  cyclophosphamide doxorubicin


    Martin H Dreyling: Influence Statistics

    Sample of concepts for which Martin H Dreyling is among the top experts in the world.
    Concept World rank
    dlbcl patterns #1
    everolimus maintenance #1
    granta519 #1
    international prognostic type #1
    monoclonal rituximab maintenance #1
    outpatient setting patients #1
    temsirolimus progressionfree survival #1
    prednisonelike regimen #1
    european mcl #1
    immunechemotherapies #1
    integration radioimmunotherapy #1
    rituximab induction #1
    mcl molecular basis #1
    gazyvaro gazai trial #1
    jeko1 granta519 #1
    cnsl member #1
    adapted involved #1
    patients ki67 #1
    national consensus workshop #1
    dose immunochemotherapy #1
    comparison rituximab #1
    translocation t1114q13q32 #1
    ibrutinib temsirolimus #1
    distinct lymphoma subtype #1
    soluble bcma csf #1
    cal101 bortezomib #1
    role pcnsl growth #1
    dhap treatment #1
    therapy mcl #1
    ffp 6 months #1
    thermal doses hsp27 #1
    combination ifrt #1
    g3 hyperglycemia #1
    additive killing #1
    role rit consolidation #1
    cxcl9 csf cnsl #1
    rituximab mcl #1
    4 cycles rituximab #1
    highrisk flipi #1
    characterized chromosomal #1
    consolidation induction therapy #1
    mcl highdose therapy #1
    arac melphalan #1
    trials mcl #1
    mcl network #1
    bendamustine treatment chemotherapy #1
    response site radiotherapy #1
    site radiotherapy #1
    subtype malignant #1
    ibrutinib versus temsirolimus #1

    Key People For Mantle Cell Lymphoma

    Top KOLs in the world
    Elı́as Campo
    cell lymphoma chronic lymphocytic leukemia cyclin d1
    Elaine S Jaffe
    cell lymphoma lymphoid neoplasms situ hybridization
    Martin H Dreyling
    honoraria funding speakers bureau mantle cell lymphoma
    Randy D Gascoyne
    cell lymphoma diffuse large gene expression
    Wolfgang D Hiddemann
    acute myeloid leukemia follicular lymphoma honoraria funding
    Julie Marie Vose
    consultancy funding cell lymphoma board directors

    Martin H Dreyling:Expert Impact

    Concepts for whichMartin H Dreylinghas direct influence:Mantle cell lymphoma,  Follicular lymphoma,  Cell lymphoma,  Mantle cell,  Rituximab maintenance.

    Martin H Dreyling:KOL impact

    Concepts related to the work of other authors for whichfor which Martin H Dreyling has influence:Cell lymphoma,  Diffuse large,  Monoclonal antibodies,  Multiple myeloma,  Brentuximab vedotin,  Chronic lymphocytic leukemia,  Elderly patients.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Department of Medicine III, LMU Hospital, Munich, Germany | Klinikum der Universität München, LMU, Munich, Germany; | Department of Internal Medicine III, Ludwig‐Maximilians University of Munich, Munich, Germany | Department of Medicine III, Universi